Clinical efficacy and prognosis analysis of treatment regimens for EGFR mutant non-small cell lung cancer and brain metastasis: a retrospective study

Table 4 Univariate and multivariate analysis of iPFS

Independent risk factor		Univariate analysis of iPFS			Multivariate analysis of iPFS
Independent risk factor		P value	HR value	95% CI	P value	HR value	95% CI
First line regimens	Group C + D: Group A + B	0.029	0.599	0.378–0.949	0.015	0.563	0.355–0.895
First line regimens	Group B: Group A	0.490	0.874	0.595–1.282
Age	< 70: ≥ 70	0.990	0.997	0.646–1.539
Gender	Female: male	0.985	0.997	0.706–1.407
Intracranial symptoms	No: Yes	0.026	0.676	0.479–0.955	0.014	0.647	0.458–0.915
Smoking	No: Yes	0.362	0.825	0.545–1.248
*EGFR* mutation	Sensitive mutation: others	0.003	0.346	0.173–0.690	0.002	0.333	0.167–0.665
*EGFR* mutation	21L858R :19DEL	0.778	1.052	0.741–1.493
Brain radiation therapy	Concurrent radiotherapy: others	0.148	1.432	0.880–2.430

Note: Group A: 1st generation EGFR-TKIs monotherapy; Group B: 1st generation EGFR-TKIs + pemetrexed plus cisplatin/carboplatin chemotherapy; Group C: 1st generation EGFR-TKIs + bevacizumab; Group D: 1st generation EGFR-TKIs + pemetrexed plus cisplatin/carboplatin chemotherapy + bevacizumab
Abbreviations: iPFS, intracranial progression-free survival; TKI, tyrosine kinase inhibitor

ISSN: 1471-2407